Does the media prefer PACB or TXG?

In the previous week, 10x Genomics had 4 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 9 mentions for 10x Genomics and 5 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 1.02 beat Pacific Biosciences of California's score of 0.41 indicating that 10x Genomics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Pacific Biosciences of California 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral 10x Genomics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings & valuation, TXG or FTV?

Fortive has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Fortive, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 9.04 -$43.54M -$0.17 N/A Fortive $4.24B 4.37 $579.20M $1.67 36.32

Is TXG or FTV more profitable?

Fortive has a net margin of 12.84% compared to 10x Genomics' net margin of -3.55%. Fortive's return on equity of 12.66% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -3.55% -2.86% -2.23% Fortive 12.84% 12.66% 6.98%

Does the media refer more to TXG or FTV?

In the previous week, 10x Genomics had 3 more articles in the media than Fortive. MarketBeat recorded 9 mentions for 10x Genomics and 6 mentions for Fortive. 10x Genomics' average media sentiment score of 1.02 beat Fortive's score of 0.90 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Fortive 4 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better earnings & valuation, TXG or NVMI?

Nova has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Nova, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 9.04 -$43.54M -$0.17 N/A Nova $880.58M 17.09 $259.22M $8.02 59.04

Is TXG or NVMI more profitable?

Nova has a net margin of 29.21% compared to 10x Genomics' net margin of -3.55%. Nova's return on equity of 21.77% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -3.55% -2.86% -2.23% Nova 29.21% 21.77% 12.56%

Does the media favor TXG or NVMI?

In the previous week, Nova had 1 more articles in the media than 10x Genomics. MarketBeat recorded 10 mentions for Nova and 9 mentions for 10x Genomics. Nova's average media sentiment score of 1.34 beat 10x Genomics' score of 1.02 indicating that Nova is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Nova 7 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, TXG or RVTY?

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio 10x Genomics $642.82M 9.04 -$43.54M -$0.17 N/A Revvity $2.86B 4.35 $241.20M $2.09 53.22

Is TXG or RVTY more profitable?

Revvity has a net margin of 8.26% compared to 10x Genomics' net margin of -3.55%. Revvity's return on equity of 8.00% beat 10x Genomics' return on equity. Company Net Margins Return on Equity Return on Assets 10x Genomics -3.55% -2.86% -2.23% Revvity 8.26% 8.00% 4.83%

Does the media refer more to TXG or RVTY?

In the previous week, 10x Genomics had 6 more articles in the media than Revvity. MarketBeat recorded 9 mentions for 10x Genomics and 3 mentions for Revvity. 10x Genomics' average media sentiment score of 1.02 beat Revvity's score of -0.22 indicating that 10x Genomics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment 10x Genomics 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Revvity 0 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Do analysts rate BIO.B or TXG?

10x Genomics has a consensus price target of $30.42, indicating a potential downside of 33.57%. Given 10x Genomics' stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Bio-Rad Laboratories. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bio-Rad Laboratories 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 10x Genomics 1 Sell rating(s) 10 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.20

10x Genomics (TXG) Competitors

$45.79 +4.02 (+9.62%)

Closing price 07/14/2026 04:00 PM Eastern

Extended Trading

$45.97 +0.18 (+0.39%)

As of 09:09 AM Eastern

Compare

TXG vs. PACB, FTV, NVMI, RVTY, and BIO.B

Should you buy 10x Genomics stock or one of its competitors? MarketBeat compares 10x Genomics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with 10x Genomics include Pacific Biosciences of California (PACB), Fortive (FTV), Nova (NVMI), Revvity (RVTY), and Bio-Rad Laboratories (BIO.B).

How does 10x Genomics compare to Pacific Biosciences of California?

Pacific Biosciences of California (NASDAQ:PACB) and 10x Genomics (NASDAQ:TXG) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, analyst recommendations, profitability, institutional ownership, valuation, risk, dividends and media sentiment.

10x Genomics has a net margin of -3.55% compared to Pacific Biosciences of California's net margin of -80.35%. 10x Genomics' return on equity of -2.86% beat Pacific Biosciences of California's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pacific Biosciences of California	-80.35%	-571.06%	-18.82%
10x Genomics	-3.55%	-2.86%	-2.23%

Pacific Biosciences of California has a beta of 2.29, suggesting that its stock price is 129% more volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market.

10x Genomics has higher revenue and earnings than Pacific Biosciences of California. 10x Genomics is trading at a lower price-to-earnings ratio than Pacific Biosciences of California, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pacific Biosciences of California	$160.01M	2.91	-$546.38M	-$0.43	N/A
10x Genomics	$642.82M	9.04	-$43.54M	-$0.17	N/A

Pacific Biosciences of California currently has a consensus target price of $1.83, suggesting a potential upside of 22.22%. 10x Genomics has a consensus target price of $30.42, suggesting a potential downside of 33.57%. Given Pacific Biosciences of California's higher probable upside, analysts clearly believe Pacific Biosciences of California is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pacific Biosciences of California	2 Sell rating(s)	2 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.80
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, 10x Genomics had 4 more articles in the media than Pacific Biosciences of California. MarketBeat recorded 9 mentions for 10x Genomics and 5 mentions for Pacific Biosciences of California. 10x Genomics' average media sentiment score of 1.02 beat Pacific Biosciences of California's score of 0.41 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pacific Biosciences of California	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
10x Genomics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

84.7% of 10x Genomics shares are owned by institutional investors. 3.7% of Pacific Biosciences of California shares are owned by company insiders. Comparatively, 8.8% of 10x Genomics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Summary

10x Genomics beats Pacific Biosciences of California on 13 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Fortive?

10x Genomics (NASDAQ:TXG) and Fortive (NYSE:FTV) are both measuring and control equipment companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, risk, profitability, dividends, earnings, valuation, institutional ownership and media sentiment.

Fortive has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Fortive, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	9.04	-$43.54M	-$0.17	N/A
Fortive	$4.24B	4.37	$579.20M	$1.67	36.32

In the previous week, 10x Genomics had 3 more articles in the media than Fortive. MarketBeat recorded 9 mentions for 10x Genomics and 6 mentions for Fortive. 10x Genomics' average media sentiment score of 1.02 beat Fortive's score of 0.90 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Fortive	4 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics has a beta of 2.05, suggesting that its stock price is 105% more volatile than the broader market. Comparatively, Fortive has a beta of 1.06, suggesting that its stock price is 6% more volatile than the broader market.

Fortive has a net margin of 12.84% compared to 10x Genomics' net margin of -3.55%. Fortive's return on equity of 12.66% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Fortive	12.84%	12.66%	6.98%

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 94.9% of Fortive shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 0.7% of Fortive shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

10x Genomics presently has a consensus price target of $30.42, indicating a potential downside of 33.57%. Fortive has a consensus price target of $62.91, indicating a potential upside of 3.71%. Given Fortive's higher probable upside, analysts clearly believe Fortive is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Fortive	2 Sell rating(s)	9 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

Fortive beats 10x Genomics on 9 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Nova?

10x Genomics (NASDAQ:TXG) and Nova (NASDAQ:NVMI) are both measuring and control equipment companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, media sentiment, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings.

10x Genomics presently has a consensus target price of $30.42, suggesting a potential downside of 33.57%. Nova has a consensus target price of $556.67, suggesting a potential upside of 17.55%. Given Nova's stronger consensus rating and higher probable upside, analysts plainly believe Nova is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Nova	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73

Nova has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Nova, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	9.04	-$43.54M	-$0.17	N/A
Nova	$880.58M	17.09	$259.22M	$8.02	59.04

In the previous week, Nova had 1 more articles in the media than 10x Genomics. MarketBeat recorded 10 mentions for Nova and 9 mentions for 10x Genomics. Nova's average media sentiment score of 1.34 beat 10x Genomics' score of 1.02 indicating that Nova is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Nova	7 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

10x Genomics has a beta of 2.05, indicating that its stock price is 105% more volatile than the broader market. Comparatively, Nova has a beta of 1.74, indicating that its stock price is 74% more volatile than the broader market.

84.7% of 10x Genomics shares are owned by institutional investors. Comparatively, 83.0% of Nova shares are owned by institutional investors. 8.8% of 10x Genomics shares are owned by company insiders. Comparatively, 1.0% of Nova shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Nova has a net margin of 29.21% compared to 10x Genomics' net margin of -3.55%. Nova's return on equity of 21.77% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Nova	29.21%	21.77%	12.56%

Summary

Nova beats 10x Genomics on 13 of the 16 factors compared between the two stocks.

How does 10x Genomics compare to Revvity?

10x Genomics (NASDAQ:TXG) and Revvity (NYSE:RVTY) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, dividends, analyst recommendations, media sentiment, earnings, institutional ownership, risk and valuation.

Revvity has a net margin of 8.26% compared to 10x Genomics' net margin of -3.55%. Revvity's return on equity of 8.00% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
10x Genomics	-3.55%	-2.86%	-2.23%
Revvity	8.26%	8.00%	4.83%

Revvity has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Revvity, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
10x Genomics	$642.82M	9.04	-$43.54M	-$0.17	N/A
Revvity	$2.86B	4.35	$241.20M	$2.09	53.22

10x Genomics has a beta of 2.05, meaning that its share price is 105% more volatile than the broader market. Comparatively, Revvity has a beta of 1.09, meaning that its share price is 9% more volatile than the broader market.

10x Genomics currently has a consensus target price of $30.42, suggesting a potential downside of 33.57%. Revvity has a consensus target price of $108.92, suggesting a potential downside of 2.09%. Given Revvity's higher probable upside, analysts clearly believe Revvity is more favorable than 10x Genomics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20
Revvity	2 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.13

84.7% of 10x Genomics shares are held by institutional investors. Comparatively, 86.7% of Revvity shares are held by institutional investors. 8.8% of 10x Genomics shares are held by insiders. Comparatively, 0.9% of Revvity shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, 10x Genomics had 6 more articles in the media than Revvity. MarketBeat recorded 9 mentions for 10x Genomics and 3 mentions for Revvity. 10x Genomics' average media sentiment score of 1.02 beat Revvity's score of -0.22 indicating that 10x Genomics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
10x Genomics	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Revvity	0 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Revvity beats 10x Genomics on 9 of the 15 factors compared between the two stocks.

How does 10x Genomics compare to Bio-Rad Laboratories?

Bio-Rad Laboratories (NYSE:BIO.B) and 10x Genomics (NASDAQ:TXG) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings.

0.0% of Bio-Rad Laboratories shares are owned by institutional investors. Comparatively, 84.7% of 10x Genomics shares are owned by institutional investors. 28.4% of Bio-Rad Laboratories shares are owned by insiders. Comparatively, 8.8% of 10x Genomics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Bio-Rad Laboratories has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market. Comparatively, 10x Genomics has a beta of 2.05, meaning that its stock price is 105% more volatile than the broader market.

Bio-Rad Laboratories has a net margin of 6.52% compared to 10x Genomics' net margin of -3.55%. Bio-Rad Laboratories' return on equity of 3.56% beat 10x Genomics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Bio-Rad Laboratories	6.52%	3.56%	2.49%
10x Genomics	-3.55%	-2.86%	-2.23%

Bio-Rad Laboratories has higher revenue and earnings than 10x Genomics. 10x Genomics is trading at a lower price-to-earnings ratio than Bio-Rad Laboratories, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bio-Rad Laboratories	$2.58B	3.20	$759.90M	$6.07	50.97
10x Genomics	$642.82M	9.04	-$43.54M	-$0.17	N/A

10x Genomics has a consensus price target of $30.42, indicating a potential downside of 33.57%. Given 10x Genomics' stronger consensus rating and higher probable upside, analysts plainly believe 10x Genomics is more favorable than Bio-Rad Laboratories.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bio-Rad Laboratories	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
10x Genomics	1 Sell rating(s)	10 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.20

In the previous week, 10x Genomics had 9 more articles in the media than Bio-Rad Laboratories. MarketBeat recorded 9 mentions for 10x Genomics and 0 mentions for Bio-Rad Laboratories. 10x Genomics' average media sentiment score of 1.02 beat Bio-Rad Laboratories' score of 0.00 indicating that 10x Genomics is being referred to more favorably in the news media.

Company	Overall Sentiment
Bio-Rad Laboratories	Neutral
10x Genomics	Positive

Summary

Bio-Rad Laboratories and 10x Genomics tied by winning 8 of the 16 factors compared between the two stocks.

Get 10x Genomics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TXG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TXG vs. The Competition

Export

Metric	10x Genomics	MEDICAL INFO SYS Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.30B	$1.84B	$6.86B	$12.44B
Dividend Yield	N/A	N/A	2.68%	8.42%
P/E Ratio	-269.35	76.84	26.95	24.38
Price / Sales	9.04	7.81	520.27	91.92
Price / Cash	N/A	27.73	48.59	59.36
Price / Book	7.34	5.60	10.81	6.33
Net Income	-$43.54M	-$54.76M	$3.59B	$331.02M
7 Day Performance	22.20%	-0.50%	-1.54%	-0.33%
1 Month Performance	42.12%	3.53%	2.74%	-1.29%
1 Year Performance	274.71%	0.19%	28.53%	21.30%

10x Genomics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TXG 10x Genomics	2.1695 of 5 stars	$45.79 +9.6%	$30.42 -33.6%	+267.2%	$5.30B	$642.82M	N/A	1,240	Positive News Analyst Forecast Gap Up
PACB Pacific Biosciences of California	2.2549 of 5 stars	$1.66 -1.2%	$1.83 +10.4%	+2.7%	$521.81M	$160.01M	N/A	730
FTV Fortive	3.827 of 5 stars	$63.62 +1.5%	$61.83 -2.8%	+16.3%	$19.10B	$4.16B	38.10	10,000
NVMI Nova	4.749 of 5 stars	$466.63 -0.7%	$551.25 +18.1%	+68.0%	$14.94B	$880.58M	58.18	1,612	Positive News Analyst Forecast Gap Up
RVTY Revvity	2.1264 of 5 stars	$112.85 -0.8%	$108.92 -3.5%	+12.9%	$12.69B	$2.90B	54.00	11,000

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TXG) was last updated on 7/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

10x Genomics (TXG) Competitors

TXG vs. PACB, FTV, NVMI, RVTY, and BIO.B

How does 10x Genomics compare to Pacific Biosciences of California?

Summary

How does 10x Genomics compare to Fortive?

Summary

How does 10x Genomics compare to Nova?

Summary

How does 10x Genomics compare to Revvity?

Summary

How does 10x Genomics compare to Bio-Rad Laboratories?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

10x Genomics (TXG) Competitors

TXG vs. PACB, FTV, NVMI, RVTY, and BIO.B

How does 10x Genomics compare to Pacific Biosciences of California?

Is PACB or TXG more profitable?

Which has more risk and volatility, PACB or TXG?

Which has higher earnings and valuation, PACB or TXG?

Do analysts rate PACB or TXG?

Does the media prefer PACB or TXG?

Do institutionals & insiders hold more shares of PACB or TXG?

Summary

How does 10x Genomics compare to Fortive?

Which has stronger earnings & valuation, TXG or FTV?

Does the media refer more to TXG or FTV?

Which has more risk and volatility, TXG or FTV?

Is TXG or FTV more profitable?

Do insiders and institutionals have more ownership in TXG or FTV?

Do analysts prefer TXG or FTV?

Summary

How does 10x Genomics compare to Nova?

Do analysts rate TXG or NVMI?

Which has better earnings & valuation, TXG or NVMI?

Does the media favor TXG or NVMI?

Which has more risk and volatility, TXG or NVMI?

Do insiders and institutionals hold more shares of TXG or NVMI?

Is TXG or NVMI more profitable?

Summary

How does 10x Genomics compare to Revvity?

Is TXG or RVTY more profitable?

Which has stronger valuation & earnings, TXG or RVTY?

Which has more risk and volatility, TXG or RVTY?

Do analysts recommend TXG or RVTY?

Do institutionals and insiders hold more shares of TXG or RVTY?

Does the media refer more to TXG or RVTY?

Summary

How does 10x Genomics compare to Bio-Rad Laboratories?

Do institutionals and insiders believe in BIO.B or TXG?

Which has more risk & volatility, BIO.B or TXG?

Is BIO.B or TXG more profitable?

Which has stronger valuation and earnings, BIO.B or TXG?

Do analysts rate BIO.B or TXG?

Does the media favor BIO.B or TXG?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TXG vs. The Competition

10x Genomics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools